DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS
Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.
1 . A method for treatment of an anastomotic stricture, the method comprising:
providing a balloon catheter at a target site in a body lumen comprising the anastomotic stricture, the balloon catheter comprising
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises an initial drug load of a therapeutic agent;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen;
deflating the balloon; and
withdrawing the balloon catheter from the body lumen.
2 . The method of claim 1 , wherein inserting the balloon catheter into the target site comprises inserting the balloon catheter and a scope into the target site.
3 . The method of claim 2 , wherein the scope comprises an endoscope, enteroscope, colonoscope, sigmoidoscope, rectoscope, anoscope, rhinoscope, bronchoscope, or a cystoscope.
4 . The method of claim 1 , wherein the therapeutic agent is chosen from paclitaxel, docetaxel, taxol, rapamycin, sirolimus, zotarolimus, everolimus, tacrolimus, mTOR inhibitors, analogues thereof, and combinations thereof.
5 . The method of claim 1 , wherein the balloon has thereon a residual drug amount after the withdrawing, wherein the residual drug amount is 70% or less of the initial drug load.
6 . The method of claim 1 , wherein the inflation period is from 0.1 minutes to 10 minutes.
7 . The method of claim 1 , wherein the initial drug load is from 1 to 6 micrograms of the therapeutic agent per square millimeter of the balloon at its nominal diameter.
8 . The method of claim 1 , further comprising performing a stricturotomy at the target site prior to providing the balloon catheter.
9 . The method of claim 8 , wherein the stricturotomy comprises needle knife electroincision, episiotomy, urethrotomy, direct vision internal urethrotomy (DVIU), endoscopic mucosal resection (EMR), or endoscopic sub-mucosal dissection (ESD).
10 . The method of claim 1 , wherein the anastomotic stricture is a non-vascular stricture.
11 . A method for preventing formation of an anastomotic stricture, the method comprising:
providing a balloon catheter at a target site in a body lumen where an anastomosis has been performed, the balloon catheter comprising
an elongated balloon, and
a coating layer overlying an exterior surface of the balloon, wherein the coating layer comprises an initial drug load of a therapeutic agent;
inflating the balloon at the target site to contact the coating layer with walls of the body lumen;
deflating the balloon; and
withdrawing the balloon catheter from the body lumen.
12 . The method of claim 11 , wherein providing the balloon catheter comprises inserting the balloon catheter and a scope into the target site.
13 . The method of claim 12 , wherein the scope comprises an endoscope, enteroscope, colonoscope, sigmoidoscope, rectoscope, anoscope, rhinoscope, bronchoscope, or a cystoscope.
14 . The method of claim 11 , wherein the therapeutic agent is chosen from paclitaxel, docetaxel, taxol, rapamycin, sirolimus, zotarolimus, everolimus, tacrolimus, mTOR inhibitors, analogues thereof, and combinations thereof.
15 . The method of claim 11 , wherein the balloon has thereon a residual drug amount after the withdrawing, wherein the residual drug amount is 70% or less of the initial drug load.
16 . The method of claim 11 , wherein the inflation period is from 0.1 minutes to 10 minutes.
17 . The method of claim 11 , wherein the initial drug load is from 1 to 6 micrograms of the therapeutic agent per square millimeter of the balloon at its nominal diameter.
18 . The method of claim 11 , wherein providing the balloon catheter occurs within 24 hours of performing the anastomosis.
19 . The method of claim 11 , wherein the target site is at a surgical anastomosis site chosen from an esophageal anastomosis, a stomach anastomosis, a small intestine anastomosis, a duodenum anastomosis, a jejunum anastomosis, an ileum anastomosis, a colon anastomosis, a rectum anastomosis, a large intestine anastomosis, a colorectal anastomosis, an ileocolonic anastomosis, a gastrointestinal anastomosis, a urethral anastomosis, a ureteral anastomosis, and a bladder neck anastomosis.
20 . The method of claim 11 , wherein the anastomosis is a non-vascular anastomosis.